rna
interfer
rnai
conserv
mechan
eukaryot
organ
rnaguid
regul
gene
express
doublestrand
ribonucl
acid
dsrna
inhibit
express
specif
gene
complementari
nucleotid
sequenc
play
major
role
regul
develop
genom
mainten
rnai
pathway
cellular
mechan
elimin
unwantedinvad
genet
materi
thought
evolv
part
cell
innat
immun
although
mechan
recent
uncov
concept
interfer
recur
biolog
year
came
highlight
scientist
first
discov
unexpect
gene
silenc
phenomenon
plant
flatworm
sinc
rnai
pathway
wellstudi
certain
model
organ
caenorhabd
elegan
drosophila
melanogast
arabidopsi
thaliana
knowledg
rnai
mechan
mammalian
cell
ignit
explos
research
uncov
new
mechan
gene
regul
drug
discoveri
rnai
therapeut
provid
novel
approach
conquer
dread
human
diseas
address
target
otherwis
undrugg
exist
method
medicin
review
focus
use
rnai
new
class
biolog
discoveri
rnai
preced
unexpect
outcom
experi
exogen
transgen
introduc
petunia
alter
flower
color
upregul
activ
gene
chalcon
synthas
enzym
involv
product
specif
pigment
petunia
flower
expect
overexpr
neeta
shrivastava
anshu
srivastava
b
v
patel
pharmaceut
educ
research
develop
perd
centr
ahmedabad
gujarat
india
rna
interfer
rnai
mechan
display
eukaryot
cell
rid
foreign
doublestrand
rna
molecul
rnai
demonstr
function
mammalian
cell
alter
gene
express
use
mean
genet
discoveri
well
possibl
strategi
genet
correct
rnai
first
describ
anim
cell
fire
colleagu
nematod
caenorhabd
elegan
knowledg
rnai
mechan
mammalian
cell
brought
storm
field
drug
discoveri
past
year
scientist
world
focus
exploit
therapeut
potenti
rnai
identifi
new
class
therapeut
applic
rnai
medicin
unlimit
cell
possess
rnai
machineri
henc
gene
potenti
target
therapi
rnai
develop
endogen
host
defens
mechan
mani
infect
diseas
sever
studi
demonstr
therapeut
benefit
small
interf
rna
micro
rna
anim
model
led
rapid
advanc
techniqu
research
discoveri
clinic
trial
sion
gene
would
result
darker
flower
case
complet
loss
color
observ
flowersthi
indic
introduc
transgen
affect
express
endogen
gene
thu
decreas
activ
chalcon
synthas
result
partial
white
flower
case
white
flower
endogen
gene
transgen
downregul
phenomenon
refer
cosuppress
later
renam
posttranscript
gene
silenc
ptg
initi
observ
plant
mani
laboratori
around
world
search
occurr
phenomenon
organ
demonstr
sens
rna
effect
antisens
rna
suppress
gene
express
c
elegan
soon
similar
phenomenon
call
quell
observ
fungu
neurospora
crassa
later
plant
virologist
work
improv
plant
resist
viral
diseas
observ
viral
rna
produc
transgen
also
inhibit
viral
replic
phenomenon
label
virusinduc
gene
silenc
vig
set
phenomena
collect
call
posttranscript
gene
silenc
craig
c
mello
andrew
fire
report
gene
silenc
effect
inject
dsrna
c
elegan
observ
neither
mrna
antisens
rna
inject
effect
protein
product
dsrna
success
silenc
target
gene
result
work
coin
term
rnai
discoveri
result
identif
caus
agent
previous
inexplic
phenomenon
fire
mello
award
nobel
prize
physiolog
medicin
later
phenomenon
studi
organ
rang
worm
trypanosom
fli
initi
experi
mammal
prove
disappoint
introduct
dsrna
trigger
interferon
respons
lead
alter
cellular
metabol
avoid
small
rna
chemic
synthes
use
result
desir
genespecif
silenc
establish
rnai
also
oper
mammalian
cell
subsequ
establish
small
interf
rna
sirna
mediat
mrna
degrad
process
rnai
therapeut
sirna
success
use
hepat
mous
model
follow
largescal
screen
mammalian
human
cell
fda
approv
first
clinic
trial
use
rnai
sinc
lot
research
done
variou
model
system
develop
rnai
therapeut
purpos
timelin
highlight
landmark
event
discoveri
develop
rnai
repres
fig
variou
type
small
rna
like
sirna
micro
rna
mirna
repeatassoci
sirna
rasirna
short
hairpin
rna
shrna
smallmodulatori
rna
smrna
tini
noncod
rna
tncrna
piwiinteract
rna
pirna
involv
rnai
machineri
accord
need
cell
sirna
class
nt
long
dsrna
molecul
play
varieti
role
cell
biolog
addit
role
rnai
pathway
sirna
also
act
rnairel
pathway
eg
antivir
mechan
shape
chromatin
structur
genom
sirna
first
discov
part
ptg
plant
shortli
thereaft
synthet
sirna
shown
abl
induc
rnai
mammalian
cell
discoveri
increas
interest
har
rnai
biomed
research
drug
develop
mirna
repres
class
noncod
rna
encod
genom
plant
invertebr
vertebr
found
multicellular
organ
studi
encod
gene
make
upto
predict
gene
organ
mirna
human
mirna
singlestrand
ss
rna
molecul
involv
regul
gene
express
mirna
encod
gene
transcrib
dna
translat
protein
noncod
rna
instead
process
primari
transcript
known
primirna
shortstemloop
structur
call
premirna
final
function
mirna
matur
mirna
molecul
partial
complementari
one
messeng
rna
mrna
molecul
main
function
downregul
gene
express
presenc
short
rna
transcript
first
observ
c
elegan
unlik
sirna
deriv
sens
antisens
strand
dsrna
precursor
rasirna
aris
mainli
antisens
strand
rna
interfer
landmark
event
discoveri
develop
rasirna
involv
shutdown
express
transpos
element
histon
modif
dna
methyl
modif
function
via
partli
overlap
compon
sirna
pathway
shrna
sequenc
rna
make
tight
hairpin
turn
use
silenc
gene
express
via
rnai
shrna
use
vector
introduct
cell
util
promot
ensur
express
vector
usual
pass
daughter
cell
allow
gene
silenc
inherit
shrna
hairpin
structur
cleav
cellular
machineri
sirna
follow
rnai
pathway
cell
gene
silenc
http
enwikipediaorg
smrna
short
nonproteincod
dsrna
isol
neural
stem
cell
hippocampu
adult
mice
dsrna
sequenc
stretch
dna
call
neuron
reactiv
silenc
element
evolutionarili
conserv
vertebr
bound
regulatori
protein
help
prevent
neuronspecif
gene
express
nonneuron
cell
neuron
cell
neuron
gene
express
smrna
interact
regulatori
protein
promot
gene
express
neuron
develop
class
short
rna
describ
c
elegan
unlik
mani
mirna
sequenc
tncrna
commonli
conserv
among
relat
speci
although
function
unknown
mani
complementari
mrna
might
target
degrad
pirna
class
small
rna
molecul
express
uniqu
mammalian
test
form
rnaprotein
complex
piwi
protein
pirna
complex
link
transcript
gene
silenc
retrotransposon
genet
element
germlin
cell
particularli
spermatogenesi
purif
complex
reveal
oligonucleotid
approxim
nt
longthey
distinct
size
mirna
associ
distinct
protein
complex
remain
unclear
pirna
gener
biogenesi
pathway
distinct
mirna
sirna
http
enwikipediaorg
rnai
pathway
initi
enzym
dicer
cleav
dsrna
short
doublestrand
fragment
base
pair
one
two
strand
fragment
known
guid
strand
incorpor
rnainduc
silenc
complex
risc
base
pair
mrna
molecul
induc
degrad
argonaut
catalyt
compon
risc
complex
short
rna
fragment
known
sirna
deriv
exogen
sourc
mirna
produc
rnacod
gene
cell
genom
two
class
short
rna
molecul
sirna
mirna
identifi
sequencespecif
posttranscript
regul
gene
express
although
initi
discov
unrel
studi
close
relat
molecular
characterist
biogenesi
effector
function
assembl
rnaprotein
complex
abil
regul
gene
transcript
neg
divers
eukaryot
share
common
rnase
iiiprocess
enzym
dicer
close
relat
effector
complex
risc
posttranscript
repress
dicer
cut
long
dsrna
sirna
chop
short
precursor
mirna
imperfect
stemloop
structur
mirna
gene
silenc
induc
sirna
sequencespecif
cleavag
perfectli
complementari
mrna
wherea
mirna
mediat
translat
repress
transcript
degrad
imperfectli
complementari
target
mirna
pathway
begin
transcript
primari
mirna
primirna
mirna
gene
hairpin
rna
primirna
process
nucleu
ribonucleas
drosha
becom
precursor
mirna
premirna
premirna
transport
cytoplasm
exportin
second
ribonucleas
dicer
digest
premirna
result
mirna
stage
mirna
bind
risc
align
mrna
depend
level
complementar
mirna
target
sequenc
mrna
either
translat
repress
partial
cleav
ident
plant
cleavag
appear
primari
mode
action
mammal
translat
repress
seem
key
method
fig
sirna
pathway
evolutionarili
conserv
respons
trigger
extern
introduc
dsrna
dsrna
cleav
ribonucleas
dicer
sirna
approxim
nt
sirna
load
risc
facilit
separ
two
strand
align
sirna
appropri
target
mrna
sirna
near
perfect
complementar
target
mrna
mrna
cleavag
direct
site
complementar
scientif
research
util
sirna
pathway
artifici
introduc
either
dsrna
sirna
design
degrad
target
mrnasthes
synthet
silenc
reagent
util
molecular
biolog
tool
novel
gene
identif
gene
function
analysi
biolog
pathway
screen
fig
rnai
develop
endogen
host
defens
mechan
mani
infect
diseas
defens
mechan
observ
viru
infect
plant
anim
studi
use
rnai
technolog
multipl
virus
includ
human
immunodefici
viru
hiv
influenza
viru
human
papilloma
viru
shown
promis
result
prevent
establish
product
infect
suscept
cell
addit
pathogen
virus
rnai
technolog
also
use
target
specif
cancer
gene
melanoma
pancreat
adenocarcinoma
leukemia
goal
rnaibas
therapi
activ
select
mrna
cleavag
effici
gene
silenc
achiev
either
use
viral
vector
express
shrna
resembl
microrna
precursor
introduc
sirna
mimic
dicer
cleavag
product
cytoplasm
apart
sirna
mirna
antimirna
oligonucleotid
also
studi
therapeut
import
mirna
act
natur
antisens
molecul
neg
regul
express
gene
sequenc
complementari
mirna
mirna
play
import
role
regul
mani
gene
key
pathway
variou
cellular
process
like
cell
cycl
control
apoptosi
hematopoiesi
adipocyt
differenti
insulin
secret
mani
studi
establish
link
mirna
human
diseas
cancer
neurolog
development
disord
viral
metabol
diseas
mirna
play
import
role
human
cancer
pathogenesi
dysfunct
mirna
pathway
observ
caus
neurolog
disord
like
fragil
x
syndrom
spinal
muscular
atrophi
numer
mirna
also
involv
development
regul
gene
express
mirna
also
specif
inactiv
host
cell
defens
factor
smallsiz
viral
genom
recent
report
describ
mirna
clone
varieti
virus
herp
virus
mirna
potenti
therapeut
target
treatment
diabet
obes
modifi
synthet
antimirna
oligonucleotid
amo
use
tool
specif
inhibit
individu
mirna
featur
use
unravel
function
mirna
target
synthet
sirna
har
natur
occur
rnai
pathway
manner
consist
predict
thu
make
particularli
attract
therapeut
moreov
enter
rnai
pathway
later
sirna
less
like
interfer
gene
regul
endogen
mirna
consequ
sirna
class
rnai
therapeut
advanc
preclin
clinic
studi
cancer
genet
diseas
mutat
andor
epigenet
chang
genom
lead
stepwis
deregul
cell
prolifer
cell
death
mechan
abil
rnai
silenc
diseaseassoci
gene
cell
cultur
anim
model
encourag
scientist
develop
rnaibas
therapeut
treat
diseas
includ
cancer
sirna
readili
synthes
low
product
cost
compar
protein
antibodi
therapi
addit
sirna
favor
pharmacokinet
properti
deliv
wide
rang
organ
howev
stabil
blood
deliveri
method
challeng
must
solv
develop
effect
rnai
reagent
cancer
therapi
oncogen
express
abnorm
high
level
attract
target
rnaibas
therapi
cancer
approach
effect
inhibit
tumor
growth
vivo
mous
model
one
success
studi
involv
liposom
deliveri
sirna
target
tyrosin
kinas
receptor
gene
overexpress
ovarian
cancer
cell
biweekli
deliveri
sirna
week
reduct
tumor
size
observ
rnai
therapi
combin
chemotherapi
agent
paclitaxel
reduct
tumor
size
observ
rnai
approach
also
found
help
overcom
two
major
problem
relaps
diseas
pglycoproteinmedi
drug
resist
cancer
chemotherapi
sirna
treatment
also
shown
reduc
express
bcrabl
oncoprotein
leukemia
lymphoma
cell
line
lead
apoptosi
cell
respect
futur
medic
applic
sirnabas
therapi
seem
great
potenti
combat
carcinoma
myeloma
cancer
caus
overexpress
oncoprotein
gener
oncoprotein
chromosom
transloc
point
mutat
rnai
also
provid
power
new
way
learn
gene
trigger
inhibit
cancer
effort
might
pinpoint
gene
never
link
cancer
gener
novel
idea
treatment
neurodegen
diseas
repres
one
attract
target
develop
therapeut
rnai
group
diseas
progress
loss
neuron
lead
gradual
appear
disabl
neurolog
symptom
prematur
death
current
avail
therapi
aim
improv
symptom
halt
process
neurodegener
neurodegen
diseas
classifi
either
inherit
like
huntington
diseas
hd
sporad
like
alzheim
diseas
ad
parkinson
diseas
pd
increas
preval
econom
burden
ad
pd
boost
effort
develop
intervent
rnai
therapeut
purpos
hd
rare
inherit
neurolog
disord
caus
trinucleotid
repeat
expans
huntingtin
htt
gene
result
product
mutant
htt
protein
caus
neuron
cell
death
select
area
brain
sinc
hd
caus
express
singl
gene
progress
diseas
halt
particular
gene
silenc
studi
show
mous
model
hd
treat
sirna
knockdown
express
defect
gene
observ
turn
halt
progress
diseas
rnaibas
gene
therapi
may
make
sens
correct
domin
genet
defect
inherit
neurodegen
diseas
like
huntington
diseas
amyotroph
later
sclerosi
discoveri
genet
defect
develop
cellular
anim
model
hd
reveal
pathobiolog
process
underli
ad
pd
howev
still
lack
good
anim
model
diseas
avail
screen
tool
diagnos
disord
earlier
stage
initi
studi
rnai
ad
mous
model
shown
promis
result
detail
studi
carri
nonhuman
primat
move
human
trail
rna
shown
inhibit
infect
hiv
polioviru
hepat
c
viru
hcv
cultur
cell
line
bitko
barik
success
use
sirna
silenc
gene
express
respiratori
syncyti
viru
rsv
rna
viru
caus
sever
respiratori
diseas
neonat
infant
sinc
mani
virus
success
target
rnai
like
hcv
hepat
b
viru
hbv
sever
acut
respiratori
syndrom
coronaviru
sarscov
influenza
viru
hiv
tat
rev
nef
gag
gene
silenc
result
inhibit
viral
replic
cultur
cell
mice
reduct
hbv
rna
replic
intermedi
demonstr
upon
introduct
sirna
shrna
vector
likewis
accumul
influenza
viral
mrna
arrest
follow
addit
sirna
specif
nucleocapsid
compon
rna
transcriptas
first
rnai
therapi
reach
patient
clinic
trial
aim
debilit
eye
diseas
call
macular
degener
rnai
drug
deliv
directli
diseas
tissu
ie
inject
eye
direct
deliveri
help
ensur
nake
rnai
drug
short
strand
rna
packag
protect
membran
quickli
break
bloodstream
reach
target
intact
local
deliveri
also
make
less
like
drug
unanticip
harm
effect
elsewher
bodi
diseas
trigger
protein
call
vascular
endotheli
growth
factor
vegf
promot
blood
vessel
growth
patient
macular
degener
much
protein
lead
sprout
excess
blood
vessel
behind
retina
blood
vessel
leak
cloud
often
entir
destroy
vision
new
rnai
drug
shut
gene
produc
vegf
thu
reduc
leakag
blood
vessel
result
improv
vision
success
deliveri
site
action
bottleneck
discov
drug
gener
target
drug
particular
sirna
cross
mammalian
cell
membran
unaid
two
strategi
use
deliv
sirna
vivo
one
stabli
express
sirna
precursor
shrna
viral
vector
use
gene
therapi
deliv
synthet
sirna
complex
coval
link
duplex
rna
lipid
andor
deliveri
protein
direct
local
deliveri
advantag
dose
sirna
requir
efficaci
lower
inject
administ
near
target
tissu
might
also
reduc
undesir
system
side
effect
modif
made
allow
effici
deliveri
sirna
discuss
nake
sirna
refer
deliveri
sirna
salin
simpl
excipi
dextros
sirna
directli
deliv
tissu
eye
lung
central
nervou
system
certain
cell
abil
directli
take
sirna
cytoplasm
rnai
machineri
operatesth
main
advantag
approach
eas
formul
direct
administr
target
tissu
approach
follow
initi
develop
rnai
therapeut
test
clinic
studi
anim
model
ocular
neovascular
scar
intravitr
inject
salineformul
sirna
efficaci
lipidformul
sirna
reduc
laserinduc
choroid
neovascular
mous
model
agerel
macular
degener
amd
intranas
instil
sirna
viral
gene
reduc
viral
load
rsv
parainfluenza
viru
similarli
intranas
administr
sirna
nonhuman
primat
model
sarscov
infect
inhibit
viral
replic
lung
salineformul
sirna
directli
administ
intracerebroventricular
intrathec
intraparenchym
infus
result
silenc
specif
neuron
mrna
target
multipl
region
peripher
central
nervou
system
coval
conjug
sirna
target
molecul
use
deliv
sirna
cell
use
cell
typespecif
target
conjug
one
strand
duplex
activ
conjug
attach
sens
passeng
strand
without
disrupt
activ
activ
antisens
strand
conjug
place
either
sens
strand
antisens
strand
sirna
conjug
made
use
lipophil
molecul
protein
peptid
aptam
conjug
cholesterol
adapt
achiev
effect
vivo
silenc
sirna
natur
ligand
like
transferrin
folat
rgd
argglyasp
peptid
membran
permeant
peptid
penetratin
transportan
directli
conjug
sirna
duplex
facilit
deliveri
vitro
sirna
also
conjug
rna
aptam
deliveri
specif
cell
type
liposom
formul
improv
pharmacokinet
properti
decreas
toxic
drug
polar
drug
entrap
aqueou
center
liposom
liposom
fuse
cell
membran
enhanc
drug
deliveri
cell
lipid
complex
nucleic
acid
form
amorph
particl
known
lipoplex
lipoplex
form
mix
sirna
transfect
agent
like
lipofectamin
liposom
lipoplex
extens
use
deliv
sirna
vitro
vivo
local
system
administr
sirna
use
liposom
lipoplex
shown
promis
result
local
inject
liposom
lipoplex
effect
deliv
sirna
target
cell
eye
nervou
system
tumor
area
increas
interest
direct
applic
lipoplex
sirna
mucos
surfac
vagina
intestin
rel
easi
access
mucos
site
larg
number
viral
infect
enter
bodi
mucos
portal
gener
toler
sirnalipid
formul
robust
vivo
deliveri
mucos
administr
lipid
formul
sirna
fertil
area
develop
futur
rnai
therapeut
sirna
also
complex
cation
peptid
polym
ionic
interact
neg
charg
phosphat
backbon
form
stabl
nanoparticl
prevent
aggreg
stabil
particl
size
molecul
polyethylen
glycol
peg
incorpor
peg
group
also
improv
pharmacokinet
profil
particl
shield
posit
charg
surfac
stick
neg
charg
cell
membran
result
rapid
clearanc
circul
one
wide
studi
polym
deliveri
nucleic
acid
polyethylenimin
pei
pei
polym
synthet
linear
branch
structur
high
cation
charg
densiti
cation
polyplex
form
pei
sirna
interact
cell
surfac
electrostat
endocytos
cell
disrupt
low
endosom
ph
peisirna
complex
report
show
therapeut
benefit
vivo
number
diseas
model
main
disadvantag
use
pei
therapeut
deliveri
vehicl
extrem
toxic
seen
higher
dose
synthet
polyc
consist
histidin
polylysin
residu
also
evalu
deliveri
sirna
seem
improv
vitro
efficaci
compar
pei
cation
peptid
also
deliv
oligonucleotid
cell
sever
peptidebas
gene
deliveri
system
form
peptid
like
penetratin
promot
uptak
noncoval
bound
sirna
vitro
peptidebas
approach
also
coupl
deliveri
system
liposom
enabl
target
deliveri
sirna
antibodi
also
use
specif
target
deliveri
sirna
vitro
studi
observ
protamineantibodi
fusion
protein
effici
deliv
noncoval
bound
sirna
hivenvelopexpress
melanoma
cell
hivinfect
primari
cell
protamin
fragment
bind
sirna
fab
fragment
hiv
envelop
antibodi
mediat
receptorspecif
bind
cell
express
hiv
envelop
protein
sirna
antibodyprotamin
complex
administ
intratumor
intraven
specif
deliv
sirna
subcutan
tumor
retard
growth
recent
fusion
protein
target
human
white
blood
cell
reveal
select
target
strategi
vitro
vivo
studi
demonstr
potenti
antibodi
direct
sirna
select
cell
vivo
initi
step
involv
identifi
lead
sirna
candid
bioinformat
design
vitro
studi
determin
efficaci
verifi
unwant
effect
absent
introduc
chemic
modif
improv
stabil
specif
three
import
attribut
consid
design
select
sirna
potenc
specif
nucleas
stabil
establish
effici
rnai
therapeut
agent
anoth
import
paramet
effici
deliveri
sirna
target
tissu
unwant
effect
avoid
minim
silenc
gene
share
partial
homolog
sirna
stimul
immun
system
due
certain
sirna
mammalian
cell
rnai
activ
introduc
sirna
mimic
dicercleav
endogen
mirna
effect
sirna
identifi
empir
test
base
common
featur
done
use
algorithm
avail
web
algorithm
increas
chanc
identifi
activ
sirna
imperfect
sometim
miss
potent
sirna
anoth
altern
identifi
activ
sirna
test
sequenc
experiment
select
group
candid
induc
effect
silenc
lowest
concentr
studi
also
suggest
use
slightli
longer
sirna
dicer
substrat
maintain
silenc
activ
longer
sirna
complic
synthes
activ
undesir
immun
respons
design
sirna
also
done
manipul
strand
select
singl
nt
substitut
duplex
favor
incorpor
risc
increas
chanc
identifi
potent
duplex
rnaimedi
silenc
gene
express
highli
specif
nevertheless
sirna
also
recogn
interfer
express
mrna
share
partial
homolog
target
mrna
although
alter
mrna
level
offtarget
gene
usual
less
threefold
one
approach
minim
offtarget
effect
care
design
sirna
minim
complementari
region
offtarget
gene
either
strand
sirna
duplex
chemic
modif
ribos
like
modif
guid
strand
also
done
suppress
offtarget
effect
without
significantli
interf
ontarget
silenc
thu
bioinformat
design
positionspecif
sequenceindepend
chemic
modif
use
reduc
sequencerel
offtarget
effect
maintain
effici
targetmrna
silenc
sirna
also
activ
innat
immun
respons
induc
potenti
unwant
effect
dsrna
longer
nt
smaller
sirna
higher
concentr
recogn
serinethreonin
protein
kinas
pkr
thu
trigger
pathway
result
global
translat
blockad
cell
death
dsrna
also
potenti
activ
certain
receptor
plasmacytoid
dendrit
cell
thu
trigger
product
type
interferon
proinflammatori
cytokin
induc
nuclear
activ
minim
sirna
transfect
plasmacytoid
dendrit
cell
one
induc
interferon
express
discard
presenc
modif
sirna
duplex
also
use
minim
bind
sirna
receptor
suppress
immunostimulatori
activ
human
plasma
nake
sirna
halflif
minut
convert
sirna
drug
necessari
prolong
halflif
without
affect
biolog
activ
sirna
duplex
stabil
simpl
chemic
modif
minimum
modif
requir
stabil
particular
duplex
identifi
studi
degrad
fragment
plasma
thu
avoid
associ
toxic
chang
caus
reduc
activ
introduct
phosphorothio
ps
backbon
linkag
protect
exonucleas
degrad
modif
like
provid
endonucleas
resist
simpl
modif
stabil
sirna
duplex
maintain
silenc
activ
chemic
modif
posit
ribos
increas
sirna
stabil
provid
resist
rnase
activ
sirna
shown
provid
greater
protect
vivo
infect
hbv
compar
unmodifi
sirna
sirna
formul
carrier
system
vivo
deliveri
need
protect
nucleas
digest
especi
expos
nucleaserich
environ
blood
formul
excipi
provid
nucleas
protect
nucleasestabil
sirna
show
improv
pharmacokinet
properti
vivo
sever
studi
show
chemic
modif
nucleobas
sugar
phosphat
ester
backbon
sirna
reduc
sirna
sensit
nucleas
number
chemic
modif
observ
increas
nucleas
resist
still
abl
induc
sirnamedi
gene
silenc
provid
modif
absent
specif
region
sirna
includ
limit
extent
increas
nucleas
resist
sirna
expect
increas
vivo
silenc
effect
studi
show
unmodifi
sirna
similar
potenc
stabil
version
hydrodynam
inject
liver
contrast
anoth
studi
chemic
modif
shown
enhanc
therapeut
effect
mous
model
hbv
infect
indic
viral
infect
higher
anim
treat
unmodifi
sirna
compar
chemic
modifi
sirna
effect
nucleas
stabil
longev
mrna
silenc
still
need
determin
effici
deliveri
sirna
vital
step
rnaibas
gene
silenc
effect
rnai
therapeut
agent
greatli
depend
effici
deliveri
sirna
correct
intracellular
locat
interact
rnai
machineri
within
target
cell
within
target
tissu
respons
patholog
level
target
pose
signific
barrier
sever
strategi
develop
overcom
barrier
chemic
modif
sirna
viral
nucleic
acid
deliveri
system
nonvir
nucleic
acid
deliveri
system
method
wide
use
facilit
effici
deliveri
sirna
highpressur
intraven
iv
inject
method
larg
volum
sirna
solut
inject
circul
rel
short
time
put
recipi
risk
acut
heart
failur
also
hydrodynam
inject
deliv
sirna
throughout
bodi
thu
induc
undesir
suppress
gene
express
organ
later
mechan
method
like
electropor
sonopar
develop
deliv
sirna
target
tissu
electropor
conveni
effici
method
electr
shock
appli
membran
produc
pore
allow
neg
charg
extern
molecul
enter
cytosol
electrophoresi
electropor
found
use
intracellular
deliveri
sirna
muscl
brain
kidney
method
requir
insert
electrod
target
area
thu
involv
invas
procedur
limit
rang
applic
sonopor
method
ultrasound
use
increas
poros
cell
membran
allow
larg
molecul
surround
medium
enter
cell
method
use
deliv
sirna
whole
organ
like
heart
main
problem
encount
method
low
effici
need
address
rnai
rapidli
advanc
research
discoveri
clinic
trial
tabl
three
rnai
therapeut
current
clinic
investig
mani
other
readi
enter
trial
soon
initi
trial
focus
wellvalid
therapeut
target
vegf
pathway
wet
amd
rsv
genom
rsv
infect
approv
sirnabas
drug
use
eye
vitraven
retin
macugen
amd
direct
inject
vitreal
caviti
effici
target
sirna
drug
retina
also
sinc
ocular
compart
rel
free
nucleas
permit
unmodifi
sirna
use
vitreal
cavityth
eas
drug
deliveri
combin
valid
vegf
therapeut
target
led
rapid
develop
sever
rnai
therapeut
eye
diseas
intravitr
inject
unmodifi
sirna
complet
phase
ii
trial
patient
seriou
progress
wet
amd
report
provid
doserel
benefit
includ
near
vision
lesion
size
also
test
efficaci
diabet
macular
edema
phase
ii
trial
wwwacuitypharmacom
chemic
modifi
sirna
complet
phase
trial
patient
wet
amd
report
well
toler
also
report
stabil
improv
vision
patient
wwwsirnacom
deliveri
sirna
therapeut
directli
lung
target
lung
epitheli
cell
also
mani
advantag
lung
epitheli
cell
uptak
nake
sirna
mediat
rnai
silenc
nucleas
free
deliveri
lung
inhal
directli
target
tissu
epithelium
thu
improv
drug
concentr
target
tissu
reduc
drug
dose
decreas
chanc
system
side
effect
mani
case
nake
sirna
salin
effect
approach
optim
lung
deliveri
develop
differ
indic
first
pulmonari
studi
direct
treat
rsv
seriou
neonat
respiratori
infect
two
phase
trial
sirna
target
viral
nucleocapsid
gene
complet
found
safe
well
toler
alnylam
pharmaceut
mani
rnaibas
drug
shown
promis
result
preclin
clinic
trial
expect
potenti
develop
new
class
therapeut
tabl
initi
limit
use
rnai
technolog
therapeut
design
effect
sirna
sequenc
even
recommend
rule
sirna
design
follow
ensur
effect
silenc
target
geneth
efficaci
sirnamedi
suppress
gene
express
depend
number
factor
like
structur
sirna
recept
cell
type
sirna
uptak
halflif
target
protein
achiev
optim
silenc
import
factor
stabil
sirna
although
sirna
rel
stabl
cell
cultur
condit
requir
enhanc
nucleas
thermodynam
stabil
blood
circul
vivo
mani
type
chemic
modif
sirna
explor
enhanc
stabil
mix
opinion
modif
effect
enhanc
stabil
without
compromis
targetsilenc
activ
advanc
made
toward
goal
make
sirna
suitabl
therapeut
purpos
rnai
emerg
way
restor
health
answer
question
rnai
new
class
biolog
still
wait
author
declar
conflict
interest
